Incyte Corporation (LON: 0J9P)
London
· Delayed Price · Currency is GBP · Price in USD
71.70
-0.76 (-1.04%)
Jan 23, 2025, 2:45 PM BST
Incyte Revenue
Incyte had revenue of $1.14B USD in the quarter ending September 30, 2024, with 23.81% growth. This brings the company's revenue in the last twelve months to $4.08B, up 12.94% year-over-year. In the year 2023, Incyte had annual revenue of $3.70B with 8.87% growth.
Revenue (ttm)
$4.08B
Revenue Growth
+12.94%
P/S Ratio
n/a
Revenue / Employee
$1.61M
Employees
2,524
Market Cap
11.33B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3.70B | 301.01M | 8.87% |
Dec 31, 2022 | 3.39B | 408.37M | 13.67% |
Dec 31, 2021 | 2.99B | 319.57M | 11.98% |
Dec 31, 2020 | 2.67B | 507.94M | 23.53% |
Dec 31, 2019 | 2.16B | 276.88M | 14.71% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Incyte News
- 2 days ago - Incyte Corp (INCY) Announces Q4 and Year-End 2024 Financial Results Conference Call - GuruFocus
- 2 days ago - Incyte to Report Fourth Quarter and Year-End 2024 Financial Results - Business Wire
- 7 days ago - Incyte, Syndax get FDA okay for 9 mg, 22 mg Niktimvo vials - Seeking Alpha
- 7 days ago - Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes - PRNewsWire
- 9 days ago - Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 - Seeking Alpha
- 10 days ago - Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 12 days ago - Incyte: Multiple Drug Launches Bode Well For Future Growth - Seeking Alpha
- 12 days ago - Incyte Corporation (INCY) Announces Executive Leadership Change - GuruFocus